MedTrace Logo

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

NCT00226330 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1100

Last updated 2010-11-19

No results posted yet for this study

Summary

This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Tesaglitazar

(0.5 or 1 mg)

DRUG

Pioglitazone

(15, 30 or 45 mg)

Sponsors & Collaborators

Principal Investigators

  • Galida Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States
  • Argentina
  • Brazil
  • Canada
  • Finland
  • Mexico
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00226330 on ClinicalTrials.gov